Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists

BACKGROUND: Vedolizumab is a recently available monoclonal antibody targeting α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). OBJECTIVE: The objective of this article is to evaluate the efficacy of vedolizumab induction therapy in anti-TNF-refractory/intolerant U...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:United European Gastroenterol J
Main Authors: De Vos, Martine, Dhooghe, Barbara, Vermeire, Severine, Louis, Edouard, Mana, Fazia, Elewaut, Ann, Bossuyt, Peter, Baert, Filip, Reenaers, Catherine, Van Gossum, Marc, Macken, Elisabeth, Ferrante, Marc, Hindryckx, Pieter, Dewit, Olivier, Holvoet, Tom, Franchimont, Denis
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5949962/
https://ncbi.nlm.nih.gov/pubmed/29774158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050640617722310
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados